Prime Medicine (PRME) Non-Current Assets (2021 - 2026)
Prime Medicine's (PRME) quarterly Non-Current Assets came in at $156.8 million in Q1 2026, down 4.6% YoY from $164.4 million in Q1 2025, and down 2.85% on a QoQ basis from $161.4 million in Q4 2025.
Prime Medicine (PRME) Non-Current Assets (2021 - 2026) Analysis & Trends
Prime Medicine (PRME) has 6 years of Non-Current Assets data on file, last reported at $156.8 million in Q1 2026.
- Quarterly Non-Current Assets fell 4.6% year-over-year to $156.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $629.6 million (up 47.92% YoY) and the FY2025 annual result came in at $161.4 million, up 88.55% from the prior year.
- Non-Current Assets fell to $156.8 million in Q1 2026, from $161.4 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $164.4 million in Q1 2025 to a low of $50.9 million in Q4 2023.
- A 5-year average of $100.7 million and a median of $86.7 million in 2024 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2022 — Non-Current Assets soared 103.65% — and 2023, when it fell 20.13%.
- Tracing PRME's Non-Current Assets over 5 years: stood at $63.7 million in 2022, then declined by 20.13% to $50.9 million in 2023, then jumped by 68.3% to $85.6 million in 2024, then soared by 88.55% to $161.4 million in 2025, then retreated by 2.85% to $156.8 million in 2026.
- The last three Non-Current Assets figures came in at $156.8 million (Q1 2026), $161.4 million (Q4 2025), and $153.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Prime Medicine | 558.48 Mn | 558.48 Mn | - | 152.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 152.24 Mn |
| Mar 31, 2026 | 156.84 Mn |
| Dec 31, 2025 | 161.44 Mn |
| Sep 30, 2025 | 153.61 Mn |
| Jun 30, 2025 | 157.72 Mn |
| Mar 31, 2025 | 164.40 Mn |
| Dec 31, 2024 | 85.62 Mn |
| Sep 30, 2024 | 86.71 Mn |
| Jun 30, 2024 | 88.90 Mn |
| Mar 31, 2024 | 93.73 Mn |
| Dec 31, 2023 | 50.88 Mn |
| Sep 30, 2023 | 54.61 Mn |
| Jun 30, 2023 | 62.38 Mn |
| Mar 31, 2023 | 63.45 Mn |
| Dec 31, 2022 | 63.70 Mn |
| Sep 30, 2022 | 66.42 Mn |
| Dec 31, 2021 | 31.28 Mn |